Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor

Tomlinson, B.

Current Opinion in Investigational Drugs 7(10): 936-945

2006


ISSN/ISBN: 1472-4472
PMID: 17086939
Document Number: 8743
Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.

Document emailed within 1 workday
Secure & encrypted payments

Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor